02728nas a2200193   4500008004100000020001400041024001700055245014400072210006900216260026700285300001400552490000700566520183000573100001902403700002402422700002102446700002202467856004502489       2015                        eng d  a0041-1132  awdn, 041736000aTransfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012.0 aTransfusionrelated adverse reactions reported to the National He  a(C) 2015 John Wiley & Sons, Ltdb(1) Office of Blood, Organ and Other Tissue Safety, Division of Healthcare Quality Promotion, National Center for Emerging, Zoonotic, and Infectious Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia,c2015  a709 - 7180 v553 a<p>BACKGROUND: In 2010, health care facilities in the United States began voluntary enrollment in the National Healthcare Safety Network (NHSN) Hemovigilance Module. Participants report transfusion practices; red blood cell, platelet (PLT), plasma, and cryoprecipitate units transfused; and transfusion-related adverse reactions and process errors to the Centers for Disease Control and Prevention through a secure, Internet-accessible surveillance application available to transfusing facilities., STUDY DESIGN AND METHODS: Facilities submitting at least 1 month of transfused components data and adverse reactions from January 1, 2010, to December 31, 2012, were included in this analysis. Adverse reaction rates for transfused components, stratified by component type and collection and modification methods, were calculated., RESULTS: In 2010 to 2012, a total of 77 facilities reported 5136 adverse reactions among 2,144,723 components transfused (239.5/100,000). Allergic (46.8%) and febrile nonhemolytic (36.1%) reactions were most frequent; 7.2% of all reactions were severe or life-threatening and 0.1% were fatal. PLT transfusions (421.7/100,000) had the highest adverse reaction rate., CONCLUSION: Adverse transfusion reaction rates from the NHSN Hemovigilance Module in the United States are comparable to early hemovigilance reporting from other countries. Although severe reactions are infrequent, the numbers of transfusion reactions in US hospitals suggest that interventions to prevent these reactions are important for patient safety. Further investigation is needed to understand the apparent increased risk of reactions from apheresis-derived blood components. Comprehensive evaluation, including data validation, is important to continued refinement of the module., (C) 2015 John Wiley &amp; Sons, Ltd</p>1 aHarvey, Alexis1 aBasavaraju, Sridhar1 aChung, Koo-Whang1 aKuehnert, Matthew  uhttps://notifylibrary.org/reference/4370